Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-04-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management personnel (朱维彬) by the company's board of directors. It details the qualifications, work experience, and compliance with regulatory requirements for the appointment. There is no financial data, earnings information, or report publication mentioned. The content fits the category of announcing changes in senior management rather than a financial report or other filing types.
2024-04-29 Chinese
关于2023年度不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the company's decision not to distribute profits for the fiscal year 2023. It includes details about the audited net losses, the proposed profit distribution plan (no cash dividends, no bonus shares, no capital reserve conversion), and the rationale behind this decision. The document also contains opinions from the independent directors, audit committee, board of directors, and supervisory board, all agreeing to submit this proposal to the shareholders' meeting for approval. The content focuses on profit distribution and dividend policy rather than presenting full financial statements or comprehensive financial performance data. The document length is relatively short (1408 characters), and it serves as an official announcement of a profit distribution decision rather than a full annual report or financial statement. Therefore, it fits best into the category of Notice of Dividend Amount (DIV), as it announces the dividend decision (no dividend) and related shareholder meeting matters.
2024-04-29 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance and supervision of the accounting firm for the fiscal year 2023. It discusses the audit firm's qualifications, audit procedures, communication with the company, and the audit report issued with a qualified opinion. The document references the 2023 annual financial audit and the audit committee's oversight role. It is not the full annual report itself but a standalone report focused on the audit firm's performance and the audit process. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and related supervisory information. The document length is 2710 characters, which is consistent with a detailed report but not a full annual report. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-29 Chinese
监事会对董事会关于2023年度保留意见审计报告涉及事项的专项说明意见
Audit Report / Information Classification · 95% confidence The document is a special explanatory opinion from the Supervisory Board regarding a qualified audit report issued by an accounting firm for the company's 2023 financial statements. It discusses the audit opinion with qualifications (保留意见审计报告) and related matters, including accounting corrections and audit evidence issues. The document is not the full audit report itself but a commentary or explanation related to the audit report. Given the content focuses on audit opinion and related explanations, it fits best under Audit Report / Information (AR). The document length is short but contains substantive explanation about the audit opinion, not merely an announcement or certification, so it is not RPA or RNS. FY 2023
2024-04-29 Chinese
独立董事2023年度述职报告（陶剑虹）
Board/Management Information Classification · 95% confidence The document is an Independent Director's 2023 Annual Work Report for 广州市香雪制药股份有限公司. It details the independent director's duties, attendance at board and shareholder meetings, opinions on various company matters including financial and governance issues, communication with auditors, and oversight of company operations and risks. It references the 2022 Annual Report, quarterly reports, and other filings but does not itself contain full financial statements or comprehensive financial performance data. The document is a detailed management and governance report focusing on the independent director's role and activities during the year, rather than a full annual report or audit report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board and senior management activities and reports.
2024-04-29 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告全文" (2023 Annual Report Full Text) of 广州市香雪制药股份有限公司 (Guangzhou Xiangxue Pharmaceutical Co., Ltd.). It contains detailed financial data, management discussion and analysis, company overview, accounting policy changes, and audited financial statements. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes sections typical of an annual report such as company information, financial highlights, management discussion and analysis, governance, social responsibility, and detailed financial statements. The presence of an audit report with a qualified opinion is also mentioned, which is common in annual reports. Therefore, this document is the official yearly report covering company activity and full financial performance, matching the definition of an Annual Report (10-K). FY 2023
2024-04-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.